For further analysis, melanoma patients were categorized into groups with high and low expression of the FER1L4 and progression-free survival (PFS) as well as overall survival (OS) were assessed using Log-rank (pa) and Gehan-Breslow-Wilcoxon tests (pb) in the group of all melanoma patients and patients having non-mutated gene BRAF (wild type, WT) and displaying V600E mutation (c. This evidence concerns the gene BRAF and melanoma.